

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet	1	of	11
		Attorney Docket Number	032077.0002.UTL1

APR 09 2002
TECH CENTER 1600/2900

+ RECEIVED

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BS	AA	3,969,287		Boehringer Mannheim GmbH	7/13/1976	
	AB	4,195,128		Bayer Aktiengesellschaft	3/25/1980	
	AC	4,229,537		New York University	10/21/1980	
	AD	4,247,642		Sumitomo Chem. Co.	1/27/1981	
	AE	4,330,440		Development Finance Corp. of New Zealand	5/18/1982	
	AF	4,661,586		The Board of Trustees of the Leland Stanford Junior University	4/28/1987	
	AG	4,745,051		The Texas A&M University System	5/17/1988	
	AH	4,816,397		Celltech Limited	3/28/1989	
	AI	5,053,224		Koprowski et al.	10/1/1991	
	AJ	5,122,464		Celltech Limited; The University Court of the Univ. of Glasgow	6/16/1992	
	AK	5,227,159		Richard A. Miller	7/13/1993	
	AL	5,281,699		Tanox Biosystems, Inc.	1/25/1994	
	AM	5,612,035		The Immune Response Corporation	3/18/1997	
	AN	5,650,150		Stephen D. Gillies	7/22/1997	
	AO	5,789,206		Myriad Genetics, Inc.	8/4/1998	
	AP	5,792,445		Bracco International B.V.	8/11/1998	
	AQ	5,861,164		The Immune Response Corp.	1/19/1999	
✓	AR	5,972,334		Genitope Corp.	10/26/1999	


Examiner Signature		Date Considered	6/24/06
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	032077.0002.UTL1
Sheet	2	of	11

APR 09 2002
CENTER 1600/2900

RECEIVED

U.S. PATENT DOCUMENTS					
W31	AS	6,099,846		The Board of Trustees of the Leland Stanford Junior University	8/8/2000

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴					
W31	AT	EP	0874054	A2		3/4/98		
	AU	IP	10-295379			11/10/98		
W31	AV	WO	00/06733	A2	Heska Corp.	2/10/2000		
W1	AW	WO	00/47228		The Scripps Research Institute	8/17/2000		
W31	AX	WO	92/08495		Abbott Biotech, Inc.	5/29/1992		
W	AY	WO	97/29769		Biomira USA Inc.	8/21/1997		
W31	AZ	WO	97/35008		The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/25/1997		
W1	BA	WO	98/30577	A1	Board of Regents, The Univ. of Texas System	7/16/1998		
W31	BB	WO	99/29732		Lexigen Pharm. Corp.	6/17/1999		
W31	BC	WO	99/46392		The Gov't. of the U.S.A., rep. by The Dept. of Health & Human Services	9/16/1999		
W31	BD	WO	99/52562		Lexigen Pharm. Corp.	10/21/1999		
W31	BE	WO	99/57981		Sloan-Kettering Institute for Cancer Research	11/18/1999		
Examiner Signature		W			Date Considered	6/24/00		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122		
		Filing Date	August 10, 2001		
		First Named Inventor	Gold		
		Group Art Unit	TBA		
		Examiner Name	TBA		
Sheet	3	of	11	Attorney Docket Number	032077.0002.UTL1

APR 09 2002
RECEIVED
PATENT CENTER 1600/2800

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MJ	BF	ARDEN, et al., "Human T-Cell Receptor Variable Gene Segment Families," <u>Immunogenetics</u> , 42:455-500 (1995)		
	BG	BENDANDI, et al., "Complete Molecular Remissions Induced by Patient-specific Vaccination Plus Granulocyte-monocyte Colony-stimulating Factor Against Lymphoma," <u>Nature Medicine</u> , 5:1171-1177 (1999)		
	BH	BERINSTEIN, et al., "Idiotypic Variation in a Human B Lymphoma Cell Line," <u>The Journal of Immunology</u> , Vol. 144, No. 2: 752-758 (1990)		
	BI	BROWN, et al., "Antiidiotype Antibody Therapy of B-Cell Lymphoma," <u>Seminars in Oncology</u> , 16:199-210 (1989)		
	BJ	BROWN, et al., "The Prognostic Significance of Immunophenotype in High-grade Non-Hodgkin's Lymphoma," <u>Histopathology</u> , Vol. 14: 621-627 (1989)		
	BK	BROWN, et al., "Treatment of B-Cell Lymphomas with Anti-idiotype Antibodies Alone and in Combination with Alpha Interferon," <u>Blood</u> , 73(3):651:661 (1989)		
	BL	CAMPBELL, et al., "Idiotypic Vaccination Against Murine B Cell Lymphoma, Humoral and Cellular Requirements for the Full Expression of Antitumor Immunity," <u>The Journal of Immunology</u> , 145:1029-1036 (1990)		
	BM	CAMPBELL, et al., "Immunotherapy of Established Murine B Cell Lymphoma, Combination of Idiotypic Immunization and Cyclophosphamide," <u>The Journal of Immunology</u> , 141:3227-3233 (1988)		
	BN	CARAYANNOPOULOS, et al., "Recombinant Human IgA Expressed in Insect Cells," <u>Proc. Natl. Acad. Sci.</u> , Vol. 91: 8348-8352 (1994)		
	BO	CASARES, et al., "Antigen-specific Downregulation of T Cells by Doxorubicin Delivered through a Recombinant MHC II-peptide Chimera," <u>Nature Biotechnology</u> , 19:142-147 (2001)		
	BP	CASPAR, et al., "Idiotypic Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formations," <u>Blood</u> , Vol. 90, No. 9, pp. 3699-3706 (November 11, 1997)		

Examiner Signature		Date Considered	6/24/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A(08-00)
Approved for use through 10/31/2002. OMB 0450-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
Sheet	4	of	11
		Attorney Docket Number	032077.0002.UTL1

RECEIVED
APR 09 2002
ENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MJ	BQ	CATON, et al., "Influenza Virus Hemagglutinin-specific Antibodies Isolated from a Combinatorial Expression Library are closely related to the Immune Response of the Donor," <u>Proc. Natl. Acad. Sci.</u> , Vol. 88: 6450-6454 (1990)	
	BR	CHEN and LEVY, "Induction of Autoantibody Responses to GM-CSF by Hyperimmunization with an Id-GM-CSF Fusion Protein," <u>The Journal of Immunology</u> , 154, pp. 3105-3117 (1995)	
	BS	CHEN, et al., "Idiotypic-Cytokine Fusion Proteins as Cancer Vaccines, Relative Efficacy of IL-2, IL-4, and Granulocyte-Macrophage Colony-Stimulating Factor," <u>The Journal of Immunology</u> , 153:4775-4787 (1994)	
	BT	CHESON, et al., "Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas," <u>J. Clin. Oncol.</u> , 17(4):1244 (1999)	
	BU	CHUNDURU, "Exploitation of the Vβ8.2 T Cell Receptor in Protection against Experimental Autoimmune Encephalomyelitis Using a Live Vaccinia Virus Vector," <u>J. Immunol.</u> , 156:4940-45, (1996)	
	BV	CHUNG, et al., "Functional three-domain single-chain T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 91:12654-12658 (1994)	
	BW	CLARK, et al., "Comparison of Human and Mouse T-Cell Receptor Variable Gene Segment Subfamilies," <u>Immunogenetics</u> , 42:531-540 (1995)	
	BX	CLEARY, et al., "Clustering of Extensive Somatic Mutations in the Variable Region of an Immunoglobulin Heavy Chain Gene from a Human B Cell Lymphoma," <u>Cell Press</u> , Vol. 44: 97-106 (1986)	
	BY	DALEY, et al., "Idiotypic-Specific Transplantation Resistance to MOPC-315: Abrogation by Post-Immunization Thymectomy," <u>The Journal of Immunology</u> , vol. 120, No. 5 (1978)	
	BZ	DOENECKE, et al., "Rapid Amplification of cDNA ends (RACE) Improves the PCR-based Isolation of Immunoglobulin Variable Region Genes from Murine and Human Lymphoma Cells and Cell Lines," <u>BTS Leukemia</u> , 11:1787-1792 (1997)	
	CA	DRANOFF, et al., "Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity," <u>Proc. Natl. Acad. Sci. USA</u> , 90(8):3539-3543 (1993)	
	CB	EILAT, et al., "Secretion of a soluble, chimeric γδ T-cell receptor – immunoglobulin heterodimer," <u>Proc. Natl. Acad. Sci. USA</u> , 89:6871-6875 (1992)	

Examiner Signature		Date Considered	6/24/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 08510031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	032077.0002.UTL1
Sheet	5	of	11

RECEIVED
APR 13 2002
PCT CENTER 1600/2900

RECEIVED

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
(13)	CC	ENGEL, et al., "High-Efficiency Expression and Solubilization of Functional T Cell Antigen Receptor Heterodimers," <u>Science</u> , 256:1318-1321 (1992)	
	CD	GEORGE, et al., "Idiotypic Vaccination as a Treatment for a B Cell Lymphoma," <u>The Journal of Immunology</u> , Vol. 141: 2168-2174 (1988)	
	CE	GILLIES, et al., "Biological Activity and in Vivo Clearance of Antitumor Antibody/Cytokine Fusion Proteins," <u>Bioconjugate Chem.</u> , 4:230-235 (1993)	
	CF	GOLD, Daniel P., "TCR V Gene Usage in Autoimmunity," <u>Current Opinion in Immunology</u> , 6:907-912 (1994)	
	CG	GOLD, et al., "T-Cell Receptor Peptides as Immunotherapy for Autoimmune Disease," <u>Critical Reviews Immunol.</u> , 17:507-10 (1997)	
	CH	GRABSTEIN, et al., "Induction of Macrophage Tumoricidal Activity by Granulocyte-Macrophage Colony-Stimulating Factor," <u>Science</u> , Vol. 232:506-508 (1986)	
	CI	GREENBERG, Philip D., "Adoptive T Cell Therapy of Tumors: Mechanisms Operative in the Recognition and Elimination of Tumor Cells," <u>Advances in Immunology</u> , 49:281-355 (1991)	
	CJ	GREGOIRE, et al., "Engineered secreted T-cell receptor $\alpha\beta$ heterodimers," <u>Proc. Natl. Acad. Sci USA</u> , Vol. 88, pp. 8077-8081 (September 1991)	
	CK	HASEMANN, et al., "High-level Production of a Functional Immunoglobulin Heterodimer in a Baculovirus Expression System," <u>Proc. Natl. Acad. Sci.</u> , 87:3942-3946 (1990)	
	CL	HASEMANN, et al., "Mutational Analysis of Arsonate Binding by a CRI _A Antibody, V _H and V _L Junctional Diversity are Essential for Binding Activity," <u>The Journal of Biological Chemistry</u> , 266:7626-7632 (1991)	
	CM	HASEMANN, et al., "Mutational Analysis of the Cross-Reactive Idiotypic of the A Strain Mouse," <u>The Journal of Immunology</u> , 147:3170-3179 (1991)	
	CN	HEUFLER, et al., "Granulocyte/Macrophage Colony-Stimulating Factor and Interleukin 1 Mediate the Maturation of Murine Epidermal Langerhans Cells into Potent Immunostimulatory Dendritic Cells," <u>J. Exp. Med.</u> , 167(2):700-05 (1988)	


Examiner Signature		Date Considered	6/24/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/927,122
			Filing Date	August 10, 2001
			First Named Inventor	Gold
			Group Art Unit	TBA
			Examiner Name	TBA
			Attorney Docket Number	032077.0002.UTL1
Sheet	6	of	11	

RECEIVED
APR 09 2002
TECH CENTER 1600/2900

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
MS	CO	HINUMA, et al., "A Novel Strategy for Converting Recombinant Viral Protein into High Immunogenic Antigen," <u>Federation of European Biochemical Societies</u> , 288:138-142 (1991)		
	CP	HSU, et al., "Tumor-Specific Idiotypic Vaccines in the Treatment of Patients with B-Cell Lymphoma - Long-Term Results of a Clinical Trial," <u>Blood</u> , Vol. 89, No. 9, pp. 3129-35 (May 1, 1997)		
	CQ	HSU, et al., "Vaccination of Patients with B-cell Lymphoma Using Autologous Antigen-pulsed Dendritic Cells," <u>Nature Medicine</u> , 2:52-58 (1996)		
	CR	HUSE, et al., "General of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <u>Science</u> , 246(4935):1275-1281 (1989)		
	CS	JIANG, et al., "Murine CD8+ Cells that Specifically Delete Autologous CD4+ T Cells Expressing Vb8 TCR: A Role of the Qa-1 Molecule," <u>Immunity</u> , 2:185-94 (1995)		
	CT	KAPPLER, et al., "Binding of a soluble $\alpha\beta$ T-cell receptor to superantigen/major histocompatibility complex ligands," <u>Proc. Natl. Acad. Sci. USA</u> , 91:8462-8466 (1994)		
	CU	KUMAR, et al., "Recombinant T Cell Receptor Molecules Can Prevent and Reverse Experimental Autoimmune Encephalomyelitis," <u>J. Immunol.</u> , 159:5150-5156 (1997)		
	CV	KURUCZ, et al., "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," <u>Proc. Natl. Acad. Sci. USA</u> , 90:3830-3834 (1993)		
	CW	KWAK, et al., "Combined Syngenic Bone Marrow Transplantation and Immunotherapy of a Murine B-Cell Lymphoma: Active Immunization with Tumor-Derived Idiotypic Immunoglobulin," <u>Blood</u> , 76(11):2411-2417 (1990)		
	CX	KWAK, et al., "Idiotypic Vaccination as Therapy for Multiple Myeloma," <u>Seminars in Hematology</u> , 36:34-37 (1999)		
	CY	KWAK, et al., "Introduction of Immune Responses in Patients with B-Cell Lymphoma Against the Surface-Immunoglobulin Idiotypic Expressed by Their Tumors," <u>N. Eng. J. Med.</u> , 327:1209-1215 (1992)		
	CZ	KWAK, et al., "Transfer of Myeloma Idiotypic-specific Immunity from an Actively Immunised Marrow Donor," <u>The Lancet</u> , 345:1016-1020 (1995)		


Examiner Signature		Date Considered	6(2466)
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/STANDARD (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	032077.0002.UTL1
Sheet	7	of	11

RECEIVED

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MYC	DA	KWAK, et al., "Vaccination with Syngeneic, Lymphoma-derived Immunoglobulin Idiotypic Combined with Granulocyte/Macrophage colony-stimulating Factor Primes Mice for a Protective T-cell Response," <u>Proc. Natl. Acad. Sci.</u> , 93:10972-10977 (1996)	
	DB	LEBOWITZ, et al., "Soluble, High-Affinity Dimers of T-Cell Receptors and Class II Major Histocompatibility Complexes: Biochemical Probes for Analysis and Modulation of Immune Responses," <u>Cell. Immun.</u> , 192:175-184 (1999)	
	DC	LEVITISKY, et al., "Immunization with Granulocyte-Macrophage Colony-Stimulating Factor-Transduced, but Not B7-1-Transduced, Lymphoma Cells Primes Idiotypic-Specific T Cells and Generates Potent Systemic Antitumor Immunity," <u>J. Immunol.</u> , 156 (10):3858-3865 (1996)	
	DD	LEVY, et al., "Mutational Hot Spots in Ig V Region Genes of Human Follicular Lymphomas," <u>J. Exp. Med.</u> , 168(2):475-489 (1988)	
	DE	LIN, et al., "Expression of T Cell Antigen Receptor Heterodimers in a Lipid-Linked Form," <u>Science</u> , 249:677-679 (1990)	
	DF	MAECKER and LEVY, "Spontaneous T Cell Antigen Receptor Variants of a Human T Leukemia Cell Line," <u>J. Immunol.</u> , 141:2994-3002, (1985)	
	DG	MALKOVSKA, et al., "Human T Cells in hu-PBL-SCID Mice Proliferate in Response to Daudi Lymphoma and Confer anti-tumour Immunity," <u>Clin. Exp. Immunol.</u> , 96:158-165 (1994)	
	DH	MALONEY, et al., "Monoclonal Anti-Idiotypic Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere With the Antitumor Effect Nor Prevent the Emergence of Idiotypic-Negative Variant Cells," <u>Blood</u> , 80(6):1502-1510 (1992)	
	DI	MASSAIA, et al., "Idiotypic Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy," <u>Blood</u> , 94:673-683 (1999)	
	DJ	MCKEEVER, et al., "Immunization with Soluble BDC 2.5 T Cell Receptor-Immunoglobulin Chimeric Protein: Antibody Specificity and Protection of Nonobese Diabetic Mice against Adoptive Transfer of Diabetes by Maternal Immunization," <u>J. Exp. Med.</u> , 184:1755-1768 (1996)	
	DK	MEEKER, et al., "A Clinical Trial of Anti-Idiotypic Therapy for B Cell Malignancy," <u>Blood</u> , 65:1349-1363 (1985)	
Examiner Signature			Date Considered 6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

APR 08 2002

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 11

Complete if Known

Application Number	09/927,122
Filing Date	August 10, 2001
First Named Inventor	Gold
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	032077.0002.UTL1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
WJS	DL	MEEKER, et al., "Emergence of Idiotype Variants During Treatment of B-Cell Lymphoma with Anti-Idiotype Antibodies," <u>N. Eng. J. Med.</u> , 312:1658-1665 (1985)	
	DM	MILLER, et al., "Treatment of B-Cell Lymphoma with Monoclonal Anti-idiotype Antibody," <u>N. Eng. J. Med.</u> , 306(9):517-522 (1982)	
	DN	MINTY, et al., "Molecular Cloning of the MCP-3 Chemokine Gene and Regulation of its Expression," <u>Eur. Cytokine Netw.</u> , 4(2):99-110 (1993)	
	DO	MORRISSEY, et al., "Granulocyte-Macrophage Colony-Stimulating Factor Augments the Primary Antibody Response by Enhancing the Function of Antigen-Presenting Cells," <u>J. Immunol.</u> , 139(4):1113-1119 (1987)	
	DP	MROCZKOWSKI, et al., "Secretion of Thermostable DNA Polymerase Using a Novel Baculovirus Vector," <u>J. Biol. Chem.</u> , 269:13522-13528 (1994)	
	DQ	MULLINAX, et al., "Identification of Human Antibody Fragment Clones Specific for Tetanus Toxoid in a Bacteriophage A Immunoexpression Library," <u>Proc. Natl. Acad. Sci. USA</u> , 87(20):8095-8099 (1990)	
	DR	NELSON, et al., "Tumor-Specific, Cytotoxic T-Lymphocyte Response After Idiotype Vaccination for B-Cell, Non-Hodgkin's Lymphoma," <u>Blood</u> , 88:580-589 (1996)	
	DS	NESBIT, et al., "Production of a Functional Monoclonal Antibody Recognizing Human Colorectal Carcinoma Cells from a Baculovirus Expression System," <u>Immunol. Methods</u> , 151:201-208 (1992)	
	DT	NOVOTNY, et al., "A soluble, single-chain T-cell receptor fragment endowed with antigen-combining properties," <u>Proc. Natl. Acad. Sci. USA</u> , 88:8646-8650 (1991)	
	DU	O'HERRIN, et al., "Analysis of the Expression of Peptide - Major Histocompatibility Complexes Using High Affinity Soluble Divalent T Cell Receptors," <u>J. Exp. Med.</u> , 186(8):1333-1345 (1997)	
	DV	ODENDAHL, et al., "Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus," <u>J. Immunol.</u> , 165(10):5970-5979 (2000)	
	DW	OFFNER, et al., "Vaccination with BV8S2 Protein Amplifies TCR-Specific Regulation and Protection Against Experimental Autoimmune Encephalomyelitis in TCR BV8S2 Transgenic Mice," <u>J. Immunol.</u> , 161:2178-2186 (1998)	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/927,122
		Filing Date	August 10, 2001
		First Named Inventor	Gold
		Group Art Unit	TBA
		Examiner Name	TBA
		Attorney Docket Number	032077.0002.UTL1
Sheet	9	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Y ³
M5	DX	OGAWA, et al., "Increase in CD95 (Fas/APO-1)-positive CD4+ and CD8+ Cells in Peripheral Blood Derived from Patients with Autoimmune Hepatitis or Chronic Hepatitis C with Autoimmune Phenomena," <u>J. Gastroenterol. Hepatol.</u> , (1):69-75 (2000)	
	DY	OKADA, et al., "TCR Vaccines for Active Immunotherapy of T Cell Malignancies," <u>J. Immunol.</u> , 159:5516-5527 (1997)	
	DZ	OPDENAKKER, et al., "Human Monocyte Chemotactic Protein-3 (MCP-3): Molecular Cloning of the cDNA and Comparison with other Chemokines," <u>Biochem. Biophys. Res. Comm.</u> , 191(2):535-542 (1993)	
	EA	ORLANDI, et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," <u>Proc. Natl. Acad. Sci. USA</u> , 86(10) 3833-3837 (1989)	
	EB	POTTER, et al., "Anti-idiotypic Antibody D12 and Superantigen SPA Both Interact with Human V _H 3-encoded Antibodies on the External Face of the Heavy Chain Involving FR1, CDR2, and FR3," <u>Molecular Immunology</u> , 35:1179-1187 (1998)	
	EC	POTTER, et al., "Staphylococcal Protein A Binding to V _H 3 Encoded Immunoglobulins," <u>Intern. Rev. Immunol.</u> , 14:291-308 (1997)	
	ED	POTTER, et al., "Staphylococcal Protein A Simultaneously Interacts with Framework Region 1, Complementarity-Determining Region 2, and Framework Region 3 on Human V _H 3- Encoding Igs ¹ ," <u>The Journal of Immunology</u> , 157:2982-2988 (1996)	
	EE	POTTER, et al., "The Cross-Reactive Idiotopes Recognized by the Monoclonal Antibodies 9G4 and LC1 are Located in Framework Region 1 of Two Non-Overlapping Subsets of Human V _H 4 Family Encoded Antibodies," <u>Scand. J. Immunol.</u> , 40:43-49 (1994)	
	EF	PROOST, et al., "Human Monocyte Chemotactic Proteins-2 and -3: Structural and Functional Comparison with MCP-1," <u>J. Leukoc. Biol.</u> , 59(1):67-74 (1996)	
	EG	RAUER and KAISER, "Demonstration of Anti-HuD Specific Oligoclonal Bands in the Cerebrospinal Fluid from Patients with Paraneoplastic Neurological Syndromes Qualitative Evidence of Anti-HuD Specific IgG-synthesis in the Central Nervous System," <u>J. Neuroimmunol.</u> , 111(1-2):241-244 (2000)	
	EH	ROWEN, et al., "The Complete 685-Kilobase DNA Sequence of the Human β T Cell Receptor Locus," <u>Science</u> , 272:1755-1762 (1996)	
	EI	RUBERTI, et al., "The Use of the RACE Method to Close Hybridoma cDNA when V Region Primers Fail," <u>Journal of Immunological Methods</u> , 173:33-39 (1994)	
	EJ	SAKATO, et al., "Suppression of MOPC-167 Growth <i>In Vivo</i> by Immunization Against the Idiotypic of the MOPC-167 Myeloma Protein," <u>Microbiol. Immunol.</u> , 23:927-931 (1979)	

Examiner Signature		Date Considered	6/24/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/927,122
			Filing Date	August 10, 2001
			First Named Inventor	Gold
			Group Art Unit	TBA
			Examiner Name	TBA
			Attorney Docket Number	032077.0002.UTL1
Sheet	10	of	11	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
Mh	EK	SANTOLI, et al., "Amplification of IL-2-Driven T Cell Proliferation by Recombinant Human IL-3 and Granulocyte-Macrophage Colony-Stimulating Factor," <u>J. Immunol.</u> , 141(20:519-526 (1988)		
	EL	SINCLAIR, et al., "PCR Strategies for Isolation of the 5' End of an Immunoglobulin-encoding Bovine cDNA," <u>Gene</u> , 167:285-289 (1995)		
	EM	SINGH and O'HAGAN, "Advances in Vaccine Adjuvants," <u>Nature Biotech.</u> , 17:1075-1081 (1999)		
	EN	SMITH, et al., "Direct Evidence for an Intracellular Role for IFN-γ" Microinjection of Human IFN-γ Induces Ia Expression on Murine Macrophages, <u>J. Immunol.</u> , 144(5):1777-1782 (1990)		
	EO	STEVENSON and GORDON, "Immunization with Idiotype Immunoglobulin Protects Against Development of B Lymphocytic Leukemia, But Emerging Tumor Cells can Evade Antibody Attack by Modulation," <u>J. Immunol.</u> , 130(2):970-973 (1983)		
	EP	TAO and LEVY, "Idiotypic/granulocyte-macrophage Colony-stimulating Factor Fusion Protein as a Vaccine for B-Cell Lymphoma," <u>Nature</u> , 362(6422):755-758 (1993)		
	EQ	TESSIER, et al., "Enhanced Secretion from Insect Cells of a Foreign Protein Fused to the Honeybee Melittin Signal Peptide," <u>Gene</u> , 98:177-183 (1991)		
	ER	VAN HALL, et al., "Identification of a Novel Tumor-Specific CTL Epitope Presented by RMA, EL-4, and MBL-2 Lymphomas Reveals Their Common Origin," <u>J. Immunol.</u> , 165:869-877 (2000)		
	ES	VAINIENE, et al., "Natural Immunodominant and Experimental Autoimmune Encephalomyelitis-Protective Determinants Within the Lewis Rat Vβ8.2 Sequence Include CDR2 and Framework 3 Idiotypes," <u>Journal of Neuroscience Research</u> , 43:137-145 (1996)		
	ET	VANDENBARK, et al., "Human TCR as Antigen: Homologies and Potentially Cross-Reactive HLA-DR2-Restricted Epitopes Within the AV and BV CDR2 Loops," <u>Critical Reviews Immunol.</u> , 20:57-83 (2000)		
	EU	WAISMAN, et al., "Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity," <u>Nature Med.</u> , 2(8):899-905 (1996)		
	EV	WARE, et al., "Human CD8+ Lymphocyte Clones Specific for T Cell Receptor VB Families Expressed on Autologous CD4+ T Cells," <u>Immunity</u> , 2:177-184 (1995)		
	EW	WARREN and CATZ, "Kinetic Profiles of Cerebrospinal Fluid Anti-MBP in Response to Intravenous MBP Synthetic Peptide DENP ₈₅ VVHFFKNIVTP ₉₆ RT in Multiple Sclerosis Patients," <u>Mult. Scler.</u> , 6(5):300-311 (2000)		

Examiner Signature		Date Considered	6/24/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. QMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/927,122	
			Filing Date	August 10, 2001	
			First Named Inventor	Gold	
			Group Art Unit	TBA	
			Examiner Name	TBA	
Sheet	11	of	11	Attorney Docket Number	032077.0002.UTL1

RECEIVED
APR 09 2002
CENTER 1601/900


NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cita No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
WZ	EX	WEBER, et al., "Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor," <i>Nature</i> , 356:793-796 (1992)		
	EY	WILSON, et al., "Results of a phase I clinical trial of T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations," <i>J. Neuroimmunol.</i> , 76:15-28 (1997)		
	EZ	YOUNG, et al., "Comparison of the Effects of IL-3, Granulocyte-Macrophage Colony-Stimulating Factor, and Macrophage Colony-Stimulating Factor in Supporting Monocyte Differentiation in Culture," <i>J. Immunol.</i> , 145(2):607-615 (1990)		
	FA	ZHANG, et al., "Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosys," <i>J. Immunol.</i> , 166(1):6-10 (2001)		
	FB	ZHANG, et al., "Increased Frequency of Interleukin 2-responsive T Cells Specific for Myelin Basic Protein and Proteolipid Protein in Peripheral Blood and Cerebrospinal Fluid of Patients with Multiple Sclerosis," <i>J. Exp. Med.</i> , 179:973-984 (1994)		

Examiner Signature		Date Considered	6/24/02
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete If Known

Application Number 032077.0002.UTL1
Filing Date August 10, 2001
First Named Inventor Gold, Daniel P.
Group Art Unit 1644
Examiner Name Amy M. Decloux
Attorney Docket Number 032077.0002.UTL1

RECEIVED

OCT 08 2002

TECH CENTER 600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
MS	AA	WO	99/18129		Weidanz, J., et al.	04-15-1999		
	AB	WO	01/93913		Weidanz, J., et al.	12-13-2001		
	AC	WO	00/31239		Bolhuis, R.	06-02-2000		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T ²
MS	AD	Jesson, M., et al., "The Immune Response to Soluble D10 TCR: Analysis of Antibody and T Cell Responses," <i>International Immunology</i> , 1(10), pg. 27-35 (1998)						
	AE	Jesson, M., et al., "Immunogenicity of Recombinant, Soluble Cell Receptors in Syngeneic Mice," <i>International Congress of Immunology Abstracts</i> , pg. 442 (1995)						
	AF	Wong, C., et al., "Recombinant Adenovirus Vaccine Encoding a Chimeric T-Cell Antigen Receptor Induces Protective Immunity Against a T-Cell Lymphoma," <i>Cancer Research</i> , 10 (60), pg. 2689-2695 (2000)						
	AG	Gascoigne, N., et al., "Secretion of a Chimeric T-Cell Receptor-Immunoglobulin Protein," <i>Proceedings of the National Academy of Sciences of USA</i> , 84 (9), pg. 2936-2940 (1987)						
	AH	Vandenbark, A., et al., "T-Cell Receptor Peptides in Treatment of Autoimmune Disease: Rationale and Potential," <i>Journal of Neuroscience Research</i> , 43 (4), pg. 391-402 (1996)						

Examiner
Signature

Date
Considered

6/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	1	of	18	Attorney Docket Number	30795-702.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
M)	1	US-6361948 B1	03-26-2002	Tricoli et al.	
	2	US-6348449 B1	02-19-2002	Weiner et al.	
	3	US-6342216 B1	01-29-2002	Fidler et al.	
	4	US-6338962	01-15-2002	Frederick M. Boyce	
	5	US-6338953 B1	01-15-2002	Boyce et al.	
	6	US-6331415 B1	12-18-2001	Cabilly et al.	
	7	US-6312718 B1	11-06-2001	Popescu et al.	
	8	US-6312690	11-06-2001	Edelman et al.	
	9	US-6309632 B1	10-20-2001	Jan M. Agosti	
	10	US-6274175 B1	08-14-2001	Gombotz et al.	
	11	US-6120807	09-19-2000	Gombotz et al.	
	12	US-6096313	08-01-2000	Jager et al.	
	13	US-6087110	07-11-2000	Wang et al.	
	14	US-6083703	07-04-2000	Wang et al.	
	15	US-6083521	07-04-2000	Acemoglu et al.	
	16	US-6080409	06-27-2000	Laus et al.	
	17	US6063905	05-16-2000	Capra et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	18	CA-2139756 Abstract	01-20-1994	Bonnem et al.		
M)	19	EP-0382381 B1	05-26-1993	Schering Corp.		
W)	20	EP-0326149 B1	08-18-1993	Green Cross Corp.		
W)	21	EP-0183350 B1	01-15-1992	Immunex Corp.		
W)	22	EP-0351876 A2	01-24-1990	Ajinomoto Co., Inc.		
	23	EP-0370656 A1	05-30-1990	Schering Corp.		

Examiner Signature		Date Considered	6/24/06
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
Examiner Name	Schwadron, Ronald B.				
Sheet	2	of	18	Attorney Docket Number	30795-702.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
ms	24	US-5891429	04-06-1999	Clark et al.	
	25	US-5891432	04-06-1999	William Soo Hoo	
	26	US-5895646	04-20-1999	Elizabeth A. Wang	
	27	US-5900238	05-04-1999	Gombotz et al.	
	28	US-5904920	05-18-1999	Dranoff et al.	
	29	US-5929196	07-27-1999	Kissel et al.	
	30	US-5942253	08-24-1999	Gombotz et al.	
	31	US-5980911	11-09-1999	Cornier et al.	
	32	US-5728377	03-17-1998	Sarris et al.	
	33	US-5602007	02-11-1997	Dunn et al.	
	34	US-5679356	10-21-1997	Bonnem et al.	
	35	US-5679347	10-21-1997	Porcelli et al.	
	36	US-5580561	12-03-1996	Cercek et al.	
	37	US-5478556	12-26-1995	Elliott et al.	
	38	US-5334379	08-02-1994	Pillai et al.	
	39	US-5179017	01-12-1993	Axel et al.	
	40	US-5229496	07-20-1993	Deeley et al.	
	41	US-5254534	10-19-1993	Tachibana et al.	
	42	US-5078996	01-07-1992	Conlon III et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
	43	FR-2658432	08-23-1991	Medgonix Group SA		
	44	JP-2000256209 Abstract	09-19-2000	Morinaga Milk Ind. Co. Ltd.		
	45	JP-10295379 Abstract	11-10-1998	GSF Forsch. Umwelt		
	46	JP-02-002390 Abstract	01-08-1990	Sumitomo Chem. Co.		
	47	JP-02-076820 Abstract	03-16-1990	Ajinomoto Co. Inc.		
Examiner Signature				Date Considered	6/27/06	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known			
				Application Number		09/927,122	
				Filing Date		August 10, 2001	
				First Named Inventor		Daniel P. Gold	
				Art Unit		1644	
Examiner Name		Schwadron, Ronald B.					
Sheet	3	of	18	Attorney Docket Number		30795-702.201	
U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
MS	48	US-5162111	11-10-1992	Grabstein et al.			
	49	US-4338397	07-06-1982	Gilbert et al.			
	50	US-4399216	08-16-1983	Axel et al.			
	51	US-4444878	04-24-1984	Henry P. Paulus			
	52	US-4468464	08-28-1984	Cohen et al.			
	53	US-4512922	04-23-1985	Jones et al.			
	54	US-4634665	01-06-1987	Axel et al.			
	55	US-4704362	11-03-1987	Itakura et al.			
	56	US-4816249	03-28-1989	Levy et al.			
	57	US-4840896	06-20-1989	Reddy et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	58	JP-62089621 Abstract	01-07-1992	Immunex Corp.			
	59	JP-64-027492 Abstract	01-30-1989	Amgen			
	60	JP 01-193227 Abstract	08-03-1989	Res Dev Corp of IP			
	61	JP 62230729 Abstract	10-09-1987	Sumitomo Pharm. Co.			
MS	62	WO98/16246	04-23-1998	Johns Hopkins U.			
MS	63	WO97/13502	04-17-1997	Immunex Corp.			
MS	64	WO96/10395	04-11-1996	CSL Ltd.			
	65	WO96/07740 w/Abstract	03-14-1996	Institut Pasteur			
MS	66	WO94/01133	01-20-1994	Schering Corp.			
MS	67	WO93/20835	10-28-1993	Schering Corp.			
MS	68	WO91/05046	04-18-1991	Immunex Corp.			
MS	69	WO88/00832	02-11-1988	Immunex Corp.			
Examiner Signature			Date Considered	6/24/06			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	4	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
M	70	WALSH, "Biopharmaceutical Benchmarks-2003," Nature Biotechnology 21 (8):865-870 (2003)			
	71	PARDOLL, "Gene-Targeted Immunotherapy of Renal Cancer," Grant No. 1U01CA061551-01 + (Abstract) http://commons.cit.nih.gov/crisp3/CRISP_LIB , accessed 9/4/2002			
	72	BENDANDI, "Role of anti-idiotypic vaccines in the modern treatment of human follicular lymphoma," Expert Rev. Anticancer Ther. 1(1):65-72 (2001)			
	73	JAFEE et al., "Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation," J. of Clin. Oncology 19(1):145-156 (2001)			
	74	SELMAYR et al., "B-Cell Lymphoma Idiotypes Chimerized by Gene Targeting Can Induce Tumor Immunity," Cancer Gene Therapy 7(3):501-506 (2000)			
	75	BENVENUTI et al., "Anti-Idiotypic DNA Vaccines for Lymphoma Immunotherapy Require the Presence of Both Variable Region Genes for Tumor Protection," Gene Therapy 7(7):605-611 (2000)			
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	5	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
mm	84	BALTIMORE et al., "Expression of the Abelson Murine Leukemia Virus Genome and of Transfected K Immunoglobulin Genes," J. of Cell. Biochem. 12th Annual UCLA Symposia Abstracts, Suppl. 7A, Abstract 0224 (1983)			
	85	BANERJI et al., "Expression of a β Globin Gene is Enhanced by Remote SV40 DNA Sequences," Cell 27:299-308 (December 1981) Part 1			
	86	BERNARD et al., "Sequences of Mouse Immunoglobulin Light Chain Genes before and after Somatic Changes," Cell 15: 1133-1144 (1978)			
	87	BIXLER and PILLAI, "Augmentation by Interleukins of the Antibody Response to a Conjugate Vaccine Against Haemophilus Influenza B," in Atassi, ed., Immunobiology of Proteins and Peptides VI, Plenum Press, New York, pp.185-190 (1991)			
	88	BONNEM, "Alpha Interferon: The Potential Drug of Adjuvant Therapy: Past Achievements and Future Challenges, Eur. J. Cancer, 27 (Suppl.4):S2-S7 (1991)			
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	6	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
W	89	BONNEM, "Granulocyte-macrophage colony stimulating factor - issues in patient management," in Maroun et al., eds., Colony-Stimulating Factors in Clinical Practice, Intl. Congress and Symposium Series No. 184, Royal Society of Medicine Services Ltd., London, pp.17-22 (1992)			
	90	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Biology and Potential Clinical Utility," in Oldham, ed. Principles of Cancer Biotherapy, 2nd ed. Marcel Dekker Inc., New York, Ch. 20, pp.585-598 (1991)			
	91	BONNEM and MORSTYN, "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Current Status and Future Development," Seminars in Oncology 15(5)(Suppl 5):46-51 (1988)			
	92	BONNEM, "Granulocyte-Macrophage Colony-Stimulating Factor: Unrealized Potential," in Murphy ed. Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology, AlphaMed Press, Dayton Ohio pp.37-47 (1991)			
	93	BONNEM et al., "Summary of Preclinical/Clinical Phase I Studies With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)," Investigational New Drugs: The Journal of New Anticancer Agents, Abstract 235, 7(4):407 (1989)			
Examiner signature				Date Considered	1/24/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	7	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
M S	94	BOSS and EMTAGE, "Expression of an Immunoglobulin Light Chain Gene in Escherichia Coli," Gene Expression, Alan R. Liss, Inc. New York, pp.513-522 (1983)			
	95	CLARK and CROCE, "An Autonomously Replicating Vector for Mammalian Cells," Plasmids and Transforming Vectors, Fed. Proc. 1983, Abstract 2384			
M S	96	COLMAN et al., "Interactions of Mouse Immunoglobulin Chains within Xenopus Oocytes," J. Mol. Biol. 160:459-474 (1982)			
	97	CREIGHTON, T.E., Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp.79-86, 1983			
	98	DOLBY et al., "Cloning and partial nucleotide sequence of human immunoglobulin μ chain cDNA from B cells and mouse-human hybridomas," PNAS USA 77(10):6027-6031 (1980)			
	99	DUMANN et al., "Influence of Thymopentin on Antibody Response and Monocyte and T Cell Function in Hemodialysis Patients Who Fail to Respond to Hepatitis B Vaccination," Nephron 55:136-140 (1990)			
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	8	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
WZ	100	FALKNER and ZACHAU, "Expression of mouse immunoglobulin genes in monkey cells," Nature 298:286-288 (1982)			
WZ	101	FRIEDMAN et al., "Introduction of the Human HPRT Gene into Mammalian Cells by an Infectious Retroviral Vector," Control of Phospholipid Metabolism, Fed. Proc. 1983, Abstract 1736			
	102	FULIANO et al., "La timopentina come terapia adiuvante nella vaccinazione anti-epatite B in soggetti non-O iporesponsivi," Minerva Medica 81(5):407-413 (1990)			
MS	103	FUJISAWA et al., "Direct expression of hepatitis B surface antigen gene in E. coli," Nucleic Acids Res. 11(11):3581-3591 (1983)			
	104	GILLIES and TONEGAWA, "Expression of cloned immunoglobulin genes introduced into mouse L cells," Nucleic Acids Res. 11(22):7981-7997 (1983)			
	105	GILLIES et al., "A Tissue-specific Transcription Enhancer Element is Located in the Major Intron of a Rearranged Immunoglobulin Heavy Chain Gene," Cell 33:717-728 (1983)			
	106	GLENNIE and STEVENSON, "Univalent antibodies kill tumour cells in vitro and in vivo," Nature 295:712-714 (1982)			
	107	GOUGH et al., "Molecular Cloning of Seven Mouse Immunoglobulin K Chain Messenger Ribonucleic Acid," Biochemistry 19:2702-2710 (1980)			
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	9	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
103	108	GOUGH, "The rearrangements of immunoglobulin genes," in Tooze et al., eds., Trends in Biochemical Sciences, Reference Edition, Vol. 6, International Union of Biochemistry and Elsevier/North-Holland, 1981, pp.203-205.			
	109	GUARENTE et al., "Improved Methods for Maximizing Expression of a Cloned Gene: a Bacterium That Synthesizes Rabbit β -Globin," Cell 20:543-553 (1980)			
	110	HEATH and PLAYFAIR, "Cytokines as immunological adjuvants," Vaccine 10(7):427-434 (1992)			
	111	HESS et al., "The effect of granulocyte-macrophage-colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients," J. of Viral Hepatitis 3:149-153 (1996)			
	112	HITZEMAN et al., "Secretion of Human Interferons by Yeast," Science 219:620-625 (1983)			
	113	HOZUMI et al., "Characterization of a mouse DNA clone containing an immunoglobulin variable region gene," Nucleic Acids Res. 5(6):1779-1799 (1978)			
114	KEMP and COWMAN, "Direct immunoassay for detecting Eschericia coli colonies that contain polypeptides encoded by cloned DNA segments," PNAS USA 78(7):4520-4524 (1981)				
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	10	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
ms	115	KNUTH et al., "Cellular and humoral immune responses against cancer: implications for cancer vaccines," Current Opinion in Immunol. 3:659-664(1991)			
	116	KUROKAWA et al., "Expression of human immunoglobulin E C Chain cDNA in E. coli," Nucleic Acids Res. 11(10:3077-3085 (1983)			
	117	LAU and KAN, "Construction of Recombinant DNA Libraries Using Expression Cosmid Vectors That Can Shuttle Between Bacteria and Mammalian Cells," Plasmids and Transforming Vectors, Fed. Prec. 1983, Abstract 2362, p.2161			
	118	LESLIE et al., "Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines," Immunol. Cell Biol. 68::107-112(1990)			
	119	LEVY, "Cytokine Fusion Proteins with Enhanced Immunogenicity," NIH Grant No. 1R01AI037219-01 (1994) - PC			
ms	120	LIESCHKE et al., "Effects of Bacterially Synthesized Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy," Annals of Internal Med. 110:357-364 (1989)			
	121	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Part 1", N. Eng. J. of Med. 327(1):28-35 (1992)			
	122	LIESCHKE and BURGESS, "Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Part 2", N. Eng. J. of Med. 317(2):99-106 (1992)			
Examiner signature				Date Considered	6/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	11	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
jm	123	MARTIN et al., "Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in the Treatment of Chronic Hepatitis B," Am. Assoc. for the Study of Liver Diseases Abstracts of Papers 16(2, Pt.2):67A, Abstract 89 (1992)			
	124	MASUCCI et al., "Chemotherapy and Immunotherapy of Colorectal Cancer," Med. Oncol. & Tumor Pharmacother. 8 (3): 207-220 (1991)			
	125	MASUCCI et al., "CM-CSF Augments the Cytotoxic Activity of Mononuclear Cells in ADCC Using MAb 17-1A Both ∞ IFN and TNF- α Acts Synergistically," Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 7-10, 1989, Abstract 143			
	126	MASUCCI et al., "Granulocyte-monocyte colony-stimulating factor agments the interleukin-2-induced cytotoxic activity of huma lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)," Cancer Immunol. Immunother. 31:231-235 (1990)			
	127	McCUNEune and MARQUIS, "Interleukin 1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor Model," Cancer Res. 50:1212-1215 (1990)			
	128	MERCEREAU-PUIJALON et al., "Expressions of Cloned Eukaryotic Genes in Microorganisma," in Pettersson et al, eds. Expression of Eukaryotic Viral and Cellular Genes, Academic Press, 1981, pp.295-303			
	129	The Merck Manual of Diagnosis and Therapy, eds. Beers M.H. and Berkow R., 17th Ed., 1999, Merck Research Laboratories, Whitehouse Station, N.J., pp. 955-962 Ch. 39			
Examiner signature				Date Considered	6/24/01




*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	12	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	130	MEUER et al., "Low-Dose Interleukin-2 Induces Systemic Immune Responses Against HBsAG in Immunodeficient Non0Responders to Hepatitis B Vaccination," The Lancet, Jan. 7, 1989, pp.15-18			
	131	MEUER et al., "Monocyte Defect in Hemodialysis Patients Supports Nonresponsiveness to Hepatitis B Vaccination and Development of HBsAG Carrier State," in Zukerman, ed., Viral Hepatitis and Liver Disease, Alan R. Liss, Inc., New York, pp.711-713 (1988)			
	132	MEUER et al., "Selective Blockade of the Antigen-Receptor-Mediated Pathway of T Cell Activation in Patients with Impaired Primary Immune Responses," J. Clin. Invest. 80:743-749 (1987)			
	133	Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, New York (1982), p. 433			
	134	MONK et al., "Heavy-Chain Mutants Derived from Y2b Mouse Myeloma: Characterization of Heavy-Chain Messenger Ribonucleic Acid, Proteins, and Secretion in Deletion Mutants and Messenger Ribonucleic Acis in Y2a Mutant Progeny," Biochem. 20:2330-2339 (1981)			
	135	MORRISON, "Transfer and Expression of Immunoglobulin Genes," Ann. Rev. Immunol. 2:239-256 (1984)			
	136	MORSTYN et al., "Pharmacology of colony-stimulating factors," in Abbott, et al., eds., Trends in Pharmacological Sciences, 10:154-159 (1989)			
Examiner signature				Date Considered	6/27/06


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	13	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ¹
MS	137	MOXON, "The scope of immunisation," The Lancet, Feb. 24, 1990, pp.448-451			
	138	MULLIGAN and BERG, "Expression of Bacterial Gene in Mammalian Cells," Science 209:1422-1427 (1980)			
	139	MULLIGAN and BERG, "Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase," PNAS USA 78(4):2072-7076 (1981)			
	140	MYERS and GUSTAFSON, "Adjuvants for Human Vaccine Usage: A Rational Design," Ch. 32 in Cryz, ed., Vaccines and Immunotherapy, Pergamon Press, Inc., New York, 1991, pp.404-410			
	141	NEUBERGER, "Expression and regulation of immunoglobulin heavy chain gene transfecting into lymphoid cells, EMBO Journal 2(8):1373-1378 (1983)			
	142	NISONOFF and RIVERS, "Recombination of a Mixture of Univalent Antibody Fragments of Different Specificity," Archives of Biochemistry and Biophysics Vol. 93, Academic Press, New York and London, pp.460-462 (1961)			
	143	O'BRIEN et al., "Cloning and sequencing of the cDNA for ovine granulocyte-macrophage colony-stimulating factor (GM-CSF): Immunol. And Cell Biol. 69:51-55 (1991)			
Examiner Signature				Date Considered	6/24/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	14	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
VM	144	OCHI et al., "Functional Immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells," PNAS USA 80:6351-6355 (1983)			
	145	OCHI et al., "Transfer of a cloned immunoglobulin light-chain gene to mutant hybridoma cells restores specific antibody production," Nature 302:340-342 (1983)			
	146	OI et al., "Immunoglobulin gene expression in transformed lymphoid cells," PNAS USA 80:825-829 (1983)			
	147	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," Molecular and Cell. Biol. 3(2):280-289 (1983)			
	148	PELLICER et al., "Altering Genotype and Phenotype by DNA-Medicated Gene Transfer," Science 209:1414-1421 (1980)			
	149	PICARD and SCHAFFNER, "Correct transcription of a cloned mouse immunoglobulin gene in vivo," PNAS USA 80:417-421 (1983)			
	150	QUIROGA et al., "Recombinant γ -Interferon as Adjuvant to Hepatitis B Vaccine in Hemodialysis Patients," Hepatology 12(4):661-663 (1990)			
Examiner signature				Date Considered	6/24/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	15	of	18	Attorney Docket Number	30795-702.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Wm	151	RASO and GRIFFIN, "Hybrid Antibodies with Dual Specificity for the Delivery of Ricin to Immunoglobulin-bearing Target Cells," Cancer Res. 41:2073-2078 (1981)	
Wm	152	REEVES et al., "Construction and Transfer into Mammalian Cells of a Vector Containing Insect Histone Genes," in Lurquin, et al., eds., Genetic Engineering in Eukaryotes, Plenum Press, New York, pp.73-85 (1983)	
	153	Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton PA 1990	
Wm	154	RICE et al., "Expression of Immunoglobulin Genes introduced into Mouse Lymphoid Cell Lines," J. Cell. Biochem. Suppl 7A:133 (Abstract 0341) (1983)	
	155	RICE and BALTIMORE, "Regulated expression of an immunoglobulin K gene introduced into a mouse lymphoid cell line," PNAS USA 79:7862-7865 (1982)	
	156	ROBERTS, et al., "A general method for maximizing the expression of a cloned gene," PNAS USA 76(2):760-764 (1979)	
	157	ROBERTS, "A lac Promoter System for the Overexpression of Prokaryotic and Eukaryotic Genes in E. coli," in Rodriguez, et al., eds., Promoters, Structure and Function, Praeger Publishers, New York, 1982, pp.452-461	
J	158	ROBERTS et al., "Synthesis of simian virus 40 t antigen in Escherichia coli," PNAS USA 76(11):5596-5600 (1979)	
Examiner signature			Date Considered
			6/24/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	16	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
WJ	159	SAMBROOK et al., "Cloning into Bacteriophage M13 Vectors and Transfection of Competent Bacteria," in Molecular Cloning, A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, New York, 1989, pp.4.33-4.34			
	160	SCHRADER, "Peptide Regulatory Factors and Optimization of Vaccines," Mol. Immunol. 28(3):295-299 (1991) - PC			
	161	SIMS et al., "Somatic Mutation in Genes for the Variable Portion of the Immunoglobulin Heavy Chain," Science 216:309-311 (1982)			
	162	SOUTHERN and BERG, "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter," J. of Mol. And App. Genetics 1:327-341 (1982)			
	163	STAFFORD and QUEEN, "Cell-type specific expression of a transfected immunoglobulin gene," Nature 306:77-79 (1983)			
Examiner signature				Date Considered	6/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	17	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
MJ	164	STEWART et al., "Clinical Studies with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor," International J. of Cell Cloning 8:335-346, Suppl. 1 (1990)			
	165	STEWART et al., "Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions-a phase I dose-toxicity study," Br. J. Cancer 59:142-145 (1989)			
	166	SUBRAMANI, "Expression of the Mouse Dihydrofolate REductase Complementary Deoxyribonucleic Acid in Simian Virus 40 Vectors," Mol. And Cell Biol. 2:854-864 (1981)			
	167	SULLIVAN and MANDELL, "The role of cytokines in infection," Curr. Op. in Infectious Diseases 4:344-349 (1991)			
	168	TAN et al. Biotechn. Appl. Biochem. 1999;30:59-64			
	169	TANIGUCHI et al., "Expression of the human fibroblast interferon gene in Escherichia coli," PNAS USA 77(9):5230-5233 (1980)			
	170	TONEGAWA, "Somatic Generation of Immune Diversity," Nobel lecture, Dec. 8, 1987			
V	171	VALLE et al., "Anti-ovalbumin monoclonal antibodies interact with their antigen in internal membranes of Xenopus oocytes," Nature 300:71-74 (1982)			
Examiner signature				Date Considered	6/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/927,122
				Filing Date	August 10, 2001
				First Named Inventor	Daniel P. Gold
				Art Unit	1644
				Examiner Name	Schwadron, Ronald B.
Sheet	18	of	18	Attorney Docket Number	30795-702.201
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
W 1	172	VALLE et al., "Synthesis and secretion of mouse immunoglobulin chains from Xenopus oocytes," Nature 291:338-340 (1981)			
	173	VEELKEN et al., Rapid Expression Cloning of B Cell Lymphoma-Derived Immunoglobulin Genes for Anti-Idiotypic Vaccination and Functional Analyses of Fab-Fragments," Blood 90(10):515A (1997)			
	174	VOSE et al., "Granulocyte-monocyte colony-stimulating factor (GM-CSF): Answers or More Questions?" Annals of Internal Med. 116(3):261-262 (1992)			
	175	WETZEL et al., "Expression in Escherichia coli of a chemically synthesized gene for a "mini-C" analog of human proinsulin," Gene 16:63-71 (1981)			
	176	WIGLER et al., "Transformation of Mammalian Cells with Genes from Procaryote and Eucaryotes," Cell 16: 777-785 (1979)			
	177	WILLIAMS et al., "Cytoplasmic Inclusion Bodies in Escherichia coli Producing Biosynthetic Human Insulin Proteins," Science 215:687-689 (1982)			
Examiner signature				Date Considered	6/24/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.